When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AZRX - Dosing underway in AzurRx Bio's OPTION 2 trial of MS1819 in cystic fibrosis
AzurRx BioPharma Inc.
AzurRx BioPharma (NASDAQ:AZRX) has enrolled the first three patients in its Phase 2b OPTION 2 clinical trial to investigate lead candidate MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.
More news on: AzurRx BioPharma, Inc., Healthcare stocks news,